Literature DB >> 18254877

Proton pump-inhibiting drugs, calcium homeostasis, and bone health.

Matthew J Wright1, Deborah D Proctor, Karl L Insogna, Jane E Kerstetter.   

Abstract

Proton pump inhibitors (PPIs) are commonly used drugs, several of which are available without a prescription. Two recent studies have demonstrated increased hip fracture rates associated with PPI use. Theoretically, PPIs could impair intestinal calcium absorption resulting in increased rates of bone loss and a greater risk of fragility fracture.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18254877     DOI: 10.1111/j.1753-4887.2008.00015.x

Source DB:  PubMed          Journal:  Nutr Rev        ISSN: 0029-6643            Impact factor:   7.110


  16 in total

1.  The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

Authors:  Laura E Targownik; William D Leslie; K Shawn Davison; David Goltzman; Sophie A Jamal; Nancy Kreiger; Robert G Josse; Stephanie M Kaiser; Christopher S Kovacs; Jerilynn C Prior; Wei Zhou
Journal:  Am J Gastroenterol       Date:  2012-07-10       Impact factor: 10.864

2.  Proton pump inhibitors and fracture risk: response to comments.

Authors:  B Zhou; Y Huang; H Li; W Sun; J Liu
Journal:  Osteoporos Int       Date:  2015-11-24       Impact factor: 4.507

3.  Proton pump inhibitors: balancing the benefits and potential fracture risks.

Authors:  J Brent Richards; David Goltzman
Journal:  CMAJ       Date:  2008-08-12       Impact factor: 8.262

4.  Hip fracture and proton pump inhibitor therapy: position statement.

Authors:  Paul Moayyedi
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

5.  Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?

Authors:  Alexander L Fohl; Randolph E Regal
Journal:  World J Gastrointest Pharmacol Ther       Date:  2011-06-06

Review 6.  Emerging multifunctional roles of Claudin tight junction proteins in bone.

Authors:  Fatima Z Alshbool; Subburaman Mohan
Journal:  Endocrinology       Date:  2014-04-23       Impact factor: 4.736

Review 7.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

8.  Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.

Authors:  C Roux; J L Goldstein; X Zhou; A Klemes; R Lindsay
Journal:  Osteoporos Int       Date:  2011-03-02       Impact factor: 4.507

9.  Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects.

Authors:  Laurian Vlase; Adina Popa; Maria Neag; Dana Muntean; Sorin E Leucuta
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 10.  Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Gastroenterol Rep       Date:  2010-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.